NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 284 filers reported holding NEKTAR THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,000 | 0.0% | 19,743 | +2.6% | 0.00% | – |
Q2 2023 | $11,000 | -26.7% | 19,243 | -10.0% | 0.00% | – |
Q1 2023 | $15,000 | -67.4% | 21,378 | 0.0% | 0.00% | – |
Q4 2022 | $46,000 | -32.4% | 21,378 | +0.5% | 0.00% | – |
Q3 2022 | $68,000 | +70.0% | 21,270 | +107.8% | 0.00% | – |
Q2 2022 | $40,000 | -72.0% | 10,235 | -2.8% | 0.00% | – |
Q4 2021 | $143,000 | -36.7% | 10,528 | -16.1% | 0.00% | -100.0% |
Q3 2021 | $226,000 | -51.5% | 12,547 | -54.0% | 0.00% | 0.0% |
Q2 2021 | $466,000 | -21.4% | 27,297 | -6.8% | 0.00% | -50.0% |
Q1 2021 | $593,000 | +13.6% | 29,275 | -4.4% | 0.00% | 0.0% |
Q4 2020 | $522,000 | +29.9% | 30,635 | +25.0% | 0.00% | 0.0% |
Q3 2020 | $402,000 | -31.7% | 24,512 | -4.1% | 0.00% | -33.3% |
Q2 2020 | $589,000 | +28.0% | 25,568 | -1.9% | 0.00% | 0.0% |
Q1 2020 | $460,000 | -19.2% | 26,063 | -2.1% | 0.00% | 0.0% |
Q4 2019 | $569,000 | +22.9% | 26,631 | +3.8% | 0.00% | 0.0% |
Q3 2019 | $463,000 | -43.8% | 25,666 | +7.2% | 0.00% | -40.0% |
Q2 2019 | $824,000 | +2.1% | 23,952 | -16.6% | 0.01% | 0.0% |
Q1 2019 | $807,000 | +12.7% | 28,732 | +27.6% | 0.01% | 0.0% |
Q4 2018 | $716,000 | -47.9% | 22,515 | -4.2% | 0.01% | -50.0% |
Q3 2018 | $1,375,000 | +20.6% | 23,495 | -4.1% | 0.01% | +11.1% |
Q2 2018 | $1,140,000 | -41.8% | 24,490 | +32.9% | 0.01% | -43.8% |
Q1 2018 | $1,960,000 | +16.8% | 18,430 | -35.3% | 0.02% | +14.3% |
Q4 2017 | $1,678,000 | +93.8% | 28,485 | -21.0% | 0.01% | +100.0% |
Q3 2017 | $866,000 | +32.8% | 36,065 | +4.8% | 0.01% | +16.7% |
Q2 2017 | $652,000 | +66.8% | 34,425 | +105.8% | 0.01% | +50.0% |
Q1 2017 | $391,000 | +102.6% | 16,725 | +3.5% | 0.00% | +100.0% |
Q4 2016 | $193,000 | +2.1% | 16,156 | +47.5% | 0.00% | 0.0% |
Q3 2016 | $189,000 | +28.6% | 10,956 | +5.5% | 0.00% | – |
Q1 2016 | $147,000 | – | 10,387 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |